| [1] | Karasaki T., Moore D. A., Veeriah S., et al. (2023). Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nat. Med. 29:833−845. DOI:10.1038/s41591-023-02230-w |
| [2] | Hobor S., Al Bakir M., Hiley C. T., et al. (2024). Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nat. Commun. 15:4871. DOI:10.1038/s41467-024-47606-9 |
| [3] | Lu W.-T., Zalmas L.-P., Bailey C., et al. (2024). TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling. Nat. Cell Biol. DOI:10.1038/s41556-024-01558-w |
| [4] | Al-Rawi D. H., Lettera E., Li J., et al. (2024). Targeting chromosomal instability in patients with cancer. Nat. Rev. Clin. Oncol. 21:645−659. DOI:10.1038/s41571-024-00923-w |
| [5] | Luo M., Yang W., Bai L., et al. (2024). Artificial intelligence for life sciences: A comprehensive guide and future trends. The Innovation Life 2:100105. DOI:10.59717/j.xinn-life.2024.100105 |
| Wu F., Zhang D. and Ren T. (2025). Intratumoral heterogeneity: Targeting origin vs. variations and AI-driven non-invasive assessment. The Innovation Life 3:100123. https://doi.org/10.59717/j.xinn-life.2025.100123 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Multi-omics profiling of tumor heterogeneity and AI-based non-invasive evaluation